⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Dichlorphenamide

دی‌کلرفنامید

⚠ Unverified

🧠 Nervous SystemCarbonic anhydrase inhibitor

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Safety not established 👴 Older adults:Use with caution 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA011366

Market / country: 🇺🇸 USA

Keveyis (US)

🧮 Dose calculator

Disease / regimen

Primary periodic paralysis · Regimen source: FDA Keveyis · 2.1

• Adjust weekly by response; min 50 and max 200 mg/day. Evaluate response after 2 months. Baseline and periodic potassium and bicarbonate. FDA Keveyis · 2.1 FDA Keveyis · 2.2 FDA Keveyis · 2.3

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ Hypersensitivity to dichlorphenamide or other sulfonamides; concomitant high-dose aspirin; severe pulmonary disease; hepatic insufficiency. FDA Keveyis · 4

Warnings

• Life-threatening sulfonamide reactions (stop at first rash); hypokalaemia; metabolic acidosis; falls. FDA Keveyis · 5

Formulations

50 mg tablet (scored) — tablet 🇺🇸 USA FDA Keveyis · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Keveyis · 8.1
“Risk Summary There are no adequate data on the developmental risk associated with the use of KEVEYIS in pregnant women.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Keveyis · 8.2
“Risk Summary There are no data on the presence of dichlorphenamide in human milk, the effects on the breastfed infant, or the effects on milk production.”
👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Keveyis · 8.4
“Safety and effectiveness of KEVEYIS in pediatric patients have not been established.”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Keveyis · 8.5
“The risk of falls and of metabolic acidosis are greater in elderly patients [see Warnings and Precautions (5.4 , 5.5) ] .”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA011366
DailyMed (FDA label)FDA Keveyis
MedlinePlus (NIH)❌ None
WHO ATC/DDD❌ None
Darooyab (Iran)❌ None

🇮🇷 Not found in Iran list Darooyab · search

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Keveyis · 3 FDA Keveyis · 2.1 FDA Keveyis · 2.2 FDA Keveyis · 2.3 FDA Keveyis · 4 FDA Keveyis · 5 FDA Keveyis · SPL approval / marketing category FDA Keveyis · 8.1 FDA Keveyis · 8.2 FDA Keveyis · 8.4 FDA Keveyis · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · search
Clinical review⚠ Unverified

🔗 Similar drugs

Same class

Acetazolamide